Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of EDP-235 with Itraconazole, Carbamazepine, and Quinidine
NCT05594602Phase 1Completed
- Sponsor
- Enanta Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zevotrelvir in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Enanta Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration of EDP-235 at Day 13 and Area Under the Plasma Concentration-Time Curve of EDP-235 at Day 13. Started Oct 2022; status: completed.
02
Drugs
zevotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05594602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594602.